CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
depot medroxyprogesterone acetatedrug
Likely dose
depot medroxyprogesterone acetate 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01791413
NCT01791413Phase 2Completed
CompareCT.gov

Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas

Mahidol University·interventional·Posted Feb 15, 2013·Updated Sep 9, 2013

In Brief

A Phase 2 clinical trial evaluating depot medroxyprogesterone acetate for Endometriosis. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the ovarian reserve changes after preoperative depot medroxyprogesterone acetate (DMPA) in women with ovarian endometrioma undergoing laparoscopic cystectomy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
CountriesThailand
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 15, 2013
Enrollment StartMar 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 13.4 years ago

Interventions

depot medroxyprogesterone acetatedrug

DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)